A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)



Status:Recruiting
Conditions:Infectious Disease, Women's Studies, Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery, Immunology / Infectious Diseases, Reproductive
Healthy:No
Age Range:9 - 26
Updated:5/5/2014
Start Date:December 2013
End Date:August 2017
Contact:Toll Free Number
Phone:1-888-577-8839

Use our guide to learn which trials are right for you!

A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose Regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Administered in Preadolescents and Adolescents (9 to 14 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)

This study is a 37-month safety and immunogenicity study conducted in boys and girls 9 to 14
years of age and in females 16 to 26 years of age. From this study, the goal is to establish
that the investigational 2-dose regimens (0, 6 months and 0, 12 months) studied in boys and
girls 9 to 14 years of age are generally safe and immunogenic, with an antibody response
that is not inferior to that observed in females 16 to 26 years of age (the core efficacy
population, assessed concurrently in this study) who received the standard 3-dose regimen of
V503.


Inclusion Criteria:

All Participants:

-Judged to be in good physical health on the basis of medical history, physical
examination and laboratory results

Boys and Girls 9 to 14 Years:

-Must not have had coitarche and does not plan on becoming sexually active during the
vaccination period

Women 16 to 26 Years:

- Has never had a Pap test or only had normal Pap test results

- A lifetime history of 0 to 4 male and/or female sexual partners

Exclusion Criteria:

All Participants:

- Known allergy to any vaccine component

- History of severe allergic reaction that required medical intervention

- Thrombocytopenia or any coagulation disorder

- Females only: participant is pregnant or expecting to donate eggs during day 1
through month 7

- Currently immunocompromised, or been diagnosed with immunodeficiency

- Had a splenectomy

- Receiving or has received immunosuppressive therapies within the last year

- Received any immunoglobulin product or blood-derived product within 3 months

- Received a marketed HPV vaccine or has participated in an HPV clinical trial
We found this trial at
11
sites
Valley Village, California 91607
?
mi
from
Valley Village, CA
Click here to add this to my saved trials
?
mi
from
Augusta, GA
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Galveston, TX
Click here to add this to my saved trials
?
mi
from
Newport News, VA
Click here to add this to my saved trials
?
mi
from
Omaha, NE
Click here to add this to my saved trials
?
mi
from
Redlands, CA
Click here to add this to my saved trials
?
mi
from
South Jordan, UT
Click here to add this to my saved trials
Spring Valley, California 91978
?
mi
from
Spring Valley, CA
Click here to add this to my saved trials
?
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
?
mi
from
Woburn, MA
Click here to add this to my saved trials